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Abstract
Background: Breast cancer patients commonly report using >1 form of complementary and alternative medicine
(CAM). However, few studies have attempted to analyze predictors and outcomes of multiple CAM modalities. We
sought to group breast cancer patients by clusters of type and intensity of complementary and alternative
medicine (CAM) use following diagnosis.
Methods: Detailed CAM use following breast cancer diagnosis was assessed in 2002–2003 among 764 female
residents of Long Island, New York diagnosed with breast cancer in 1996–1997. Latent class analysis (LCA) was
applied to CAM modalities while taking into account frequency and intensities.
Results: Four distinct latent classes of CAM use emerged: 1) “Low-dose supplement users” (40 %), who used only
common nutritional supplements; 2) “Vitamin/mineral supplement users” (39 %), using an abundance of
supplements in addition to other practices; 3) “Mind-body medicine users” (12 %), with near-universal use of
supplements, mind-body medicine techniques, and massage; and 4) “Multi-modality high-dose users” (9 %), who
were highly likely to use nearly all types of CAM. Predictors of membership in classes with substantial CAM use
included younger age, more education, higher income, Jewish religion, ideal body mass index, higher fruit and
vegetable intake, higher levels of physical activity, receipt of adjuvant chemotherapy, and prior use of oral
contraceptives.
Conclusions: LCA identified important subgroups of breast cancer patients characterized by varying degrees of
complementary therapy use. Further research should explore the reproducibility of these classes and investigate the
association between latent class membership and breast cancer outcomes.
Keywords: Alternative medicine, Breast cancer, Latent class analysis, Epidemiology
Background
Complementary and alternative medicine (CAM) is gen-
erally defined to include all medical systems, practices
and products that are not part of conventional medicine
[1]. Individuals in many developed countries use CAM
for both illness treatment and disease prevention [2].
CAM use is particularly common among breast cancer
patients and survivors; in several samples more than
80 % of subjects reported using CAM [3–5], and many
reported using more than one modality [4, 6–8].
Despite high CAM use among breast cancer patients,
research of its safety and effects on breast cancer out-
comes is lacking, partly due to methodology limitations.
Prior observational studies of breast cancer patients have
operationalized CAM use as a single dichotomous variable
[9], as individual practices or products [4, 5, 8, 10, 11], or
employed broad domains of CAM [6, 12, 13] as defined
by the National Center for Complementary and Alterna-
tive Medicine [1] and others. Using data from the 2002
National Health Interview Survey, Ayers and Kronenfeld
conducted a factor analysis of CAM utilization to highlight
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categories of CAM based on actual use patterns [14].
However, the patterns identified in this population-based
sample, in which the prevalence of CAM was relatively
low and few subjects used more than one modality [15]
may not be applicable to breast cancer survivors.
Although commonly employed in observational re-
search, the analysis of broad CAM domains has been
criticized for limiting description of specific products/
techniques [13, 16], concealing differences among ther-
apies that could be related to outcomes. Conversely, in
studies that analyze the individual effects of a large num-
ber of individual practices, chance findings are likely,
and teasing out relevant associations may be limited by
interactions among modalities [3, 4, 7]. An additional
limitation of previous CAM research is the lack of con-
sideration of duration/frequency of treatment, an aspect
of CAM behavior that is particularly relevant to causal
inference regarding cancer outcomes [17].
Latent class analysis (LCA) is an increasingly popular
statistical modeling technique used to uncover hetero-
geneity in response patterns or clinical characteristics
within a population. Its use is common in the social and
behavioral sciences and unlike factor analysis, which
groups correlated response items, LCA is a person-
centered approach [18]. Grouping individuals based on
similar patterns of CAM use may address several meth-
odological concerns and provides a practical alternative
to traditional subgroup analysis to explore interactions
among modalities [19].
Here we present an exploratory latent class analysis of
CAM use among breast cancer patients who participated
in the Long Island Breast Cancer Study Project [20]. We
aim to illustrate the utility of LCA in CAM research,
and to explore demographic, clinical and behavioral pre-
dictors of different CAM user profiles.
Methods
Overview
Data for this study were obtained from the Long Island
Breast Cancer Study Project, a federally mandated case–
control study to investigate the high incidence of breast
cancer in Nassau and Suffolk counties on Long Island,
New York [20]. Cases were identified and interviewed
shortly after diagnosis in 1996–1997 and, as part of a
continuing prospective follow-up study, a second inter-
view among cases was conducted in 2002–2003, which
included a questionnaire assessing CAM use. This study
was approved by the institutional review boards of
Columbia University Medical Center, University of
North Carolina, and other collaborating institutions.
Study population
Female residents of Nassau and Suffolk counties, New
York, newly diagnosed with a first primary in situ or
invasive breast cancer were identified through a rapid
reporting system between August 1996 and July 1997,
as previously described [20]. Physician consent was ob-
tained for 1837 cases, 1508 women (82.1 %) completed
the baseline questionnaire, and 1414 agreed to subse-
quent contact. The follow-up interview was conducted
with cases or their proxies during 2002 and 2003 [21].
Only data from the 764 patients who personally com-
pleted the full follow-up questionnaire were analyzed
in this study. Non-responders to the full follow-up
questionnaire were on average older, had less education
and lower household incomes, were less likely to be
non-Hispanic white, more likely to have invasive dis-
ease, and less likely to have had a recent mammogram,
than responders, as previously reported [10]. In the
current sample, 94 % of participants were non-
Hispanic and white, and 82 % had invasive (vs in situ)
breast cancer [10].
Data collection
The baseline interview, conducted by trained inter-
viewers roughly three months after diagnosis (mean
96 days), included information on demographics, life-
style, and breast cancer risk factors. The follow-up inter-
view included questions about the first course of
treatment for the first primary breast cancer, and CAM
use before and after diagnosis and during treatment.
Signed medical records release forms were obtained
from case women to abstract data relating to tumor
characteristics and treatment during the baseline and
follow-up interviews. Informed consent was obtained
from all participants before each interview.
CAM Use assessment
The CAM section of the follow-up questionnaire included
detailed questions about 194 modalities in 7 domains that
were developed after a review of the literature: 1) vitamin/
mineral supplements; 2) herbs/botanicals; 3) non-vitamin/
mineral non-herbal over-the-counter (OTC) health prod-
ucts; 4) mind-body medicine techniques; 5) special treat-
ments (including biofeedback, colon cleansing and others);
6) diet change; and 7) practitioner-based therapies. After
an affirmative response to ever use of a particular product,
participants were asked specifically about the time follow-
ing diagnosis through the question, “How many total years
have you taken this product since diagnosis?” Frequency of
using each endorsed modality during treatment for breast
cancer was then assessed at the day, week or month level.
Although some studies have included prayer as a CAM
modality, we excluded it because a high proportion of par-
ticipants reported using it and because a separate study
had shown that prayer fit into a latent construct different
from mind-body medicine techniques [14]. We also ex-
cluded special treatments such as biofeedback, colon
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cleansing, and bioelectromagnetic-based therapy due
to very low prevalence of use (1.2 %).
We computed a “cumulative dose index” of each CAM
therapy by multiplying the reported number of years
used since diagnosis by the reported number of times
used per week or month. The cumulative dose index
value for vitamins/mineral supplements, herbs, and
over-the-counter health products was the number of
times taken per day multiplied by years taken; the value
computed for mind-body practices and CAM practi-
tioners was the number of times used per month multi-
plied by number of years used; the value for diet was the
number of years used since diagnosis.
Assessment of covariates
Covariates assessed by questionnaire at baseline included
age at diagnosis, education, annual household income,
marriage history, religion, and race/ethnicity. Known
breast cancer risk factors assessed include use of hormone
replacement therapy or oral contraceptives, and any first
degree family history of breast cancer. Medical history
and mammography were also assessed at baseline, in
addition to physical activity between menarche and diag-
nosis, fruit and vegetable intake assessed through a modi-
fied Block food frequency questionnaire, life course
alcohol use and cigarette smoking history. An unweighted
comorbidity index adapted from the Charlson Comorbid-
ity Index [22] was created. An affirmative response at the
baseline interview to a history of each of the following
conditions contributed 1 point to the index: diabetes,
asthma, myocardial infarction, stroke, gallbladder disease,
and previous cancer (0, 1, 2 or more). At the follow-up
interview, information was collected on weight and height
at diagnosis to estimate body mass index (BMI = kg/m2),
as well as the first course of treatment (chemotherapy/ra-
diation/hormone therapy) for the first primary breast
cancer.
Medical records were abstracted at baseline and again
at follow-up to ascertain information on tumor staging
(in situ vs. invasive), tumor estrogen/progesterone re-
ceptor (ER/PR) status, and first course of treatment for
the first primary breast cancer. Concordance between
the treatment data collected by interview and from
medical records was exceptionally high (kappa >90 %)
[21], and thus the information assessed by interview is
used here.
Statistical analysis
The analysis included the 23 modalities used since diag-
nosis at any dose by at least 10 % of women. Modalities
used by fewer than 10 % of women were aggregated into
six composite variables according to specified CAM do-
mains. Further, in order to increase the precision of the
latent class analysis, factor analysis was performed as a
data reduction technique prior to conducting the LCA.
A two-step process was used for the factor analysis. Be-
cause factor analysis of skewed dichotomous data using
Pearson correlation coefficients has been shown to
underestimate factor loadings [23], we first computed
tetrachoric correlations between dichotomous CAM var-
iables [24]. We then conducted the factor analysis on
the tetrachoric correlation matrix using principal axis
factoring extraction with oblique factor rotation, and de-
termined the number of factors to be retained using the
scree test [25]. Modalities that loaded on a single factor
with a factor loading of 0.3 or higher on common factors
were grouped together. Each CAM grouping generated
through factor analysis represented a subset of modal-
ities with correlated use. The cumulative dose of each
grouping was calculated by summing the cumulative
dose of all modalities making up the respective grouping.
Those not loading on any single factor were retained as
separate modalities for use in the LCA.
The summed cumulative dose index for each individ-
ual modality or CAM grouping was then categorized
into three levels with a cutoff at the median dose among
those reporting any use: (1) no use since diagnosis; (2)
use since diagnosis at a cumulative dose below the me-
dian; and (3) use since diagnosis at a cumulative dose
above the median. Latent class analysis was performed
with SAS PROC LCA [26] using the consolidated 3-level
CAM grouping variables. Models specified to contain
one through ten latent classes were evaluated based on
Akaike’s Information Criterion (AIC), Bayesian Informa-
tion Criterion (BIC), and the sample-size adjusted BIC.
We also considered the reproducibility of the model, as
defined by the percentage of iterations yielding the opti-
mal fit, as well as interpretability of the latent classes,
when determining the number of latent classes [27].
Using Bayes’ theorem, SAS PROC LCA computes each
individual’s posterior probability of membership in each
latent class. Subsequent to determining the best fitting
number of classes, participants were assigned to classes
based on maximum posterior probability. Bivariate asso-
ciations of demographic, clinical and behavior variables
with assigned latent class were examined using Pearson’s
chi-squared tests or analysis of variance (ANOVA) for
categorical and continuous variables, respectively. Ana-
lyses were performed with SAS v.9.3 (SAS Institute Inc.,
Cary, NC) using two-sided significance tests.
Results
Between diagnosis and the follow-up interview, study
participants reported using CAM practices from a median
of 2 domains (range: 0–7) (Table 1). The proportion of
women using each individual modality during treatment
for their first primary breast cancer has been previously
reported [28].
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Latent class indicators
Preliminary factor analysis identified a 3-factor solution,
suggesting that most modalities within domains tended
to be correlated in practice. However, Echinacea, green
tea, massage, and chiropractic failed to load on any sin-
gle factor (data not shown). Variables reflecting cumula-
tive dose of each CAM grouping identified, in addition
to these 4 individual modalities, were used in the latent
class analysis (total of 10 possible modalities). The cu-
mulative dose among those reporting use, as well as the
probability of using each modality at a high and low cu-
mulative dose, is reported in Table 2.
Identification and interpretation of latent classes
The primary goal of model selection was to maximize
the number of informative classes while maintaining a
balance between parsimony and stability of the models.
The 5-class model, with the lowest AIC value, was not
sufficiently stable; only 36 % of iterations were associated
with the best fitting model. According to the BIC and
sample-size adjusted BIC, the 2- and 4-class models, re-
spectively, were preferable (Table 3). After careful exam-
ination, we selected the four-class model based on the
strong repeatability and interpretability of the model.
The latent class with highest membership probability
(39.6 %) was termed “low-dose supplement users” due to
their low probability of using all CAM modalities rela-
tive to the overall sample. Despite very low CAM use by
this class, vitamin/mineral supplement use carried a 59
and 19 % estimated probability of use at a low-dose and
high-dose, respectively (Table 4). The second largest
class (39.3 %), termed “vitamin/mineral supplement
users,” was distinguished by near-universal use of vita-
mins and minerals, largely in excess of the median cu-
mulative dose, and above average probability of using
green tea and diet change. The third largest class, de-
noted “mind-body medicine users,” (11.9 %) was charac-
terized by near-ubiquitous use of mind-body medicine
techniques and massage, predominantly below the me-
dian use frequency, and less common use of several
other types of CAM. The smallest class, called “multi-
Table 1 Prevalence of using multiple domains of
complementary and alternative medicine (CAM) since
breast cancer diagnosisa
Number of CAM domains usedb n Percent
0 38 5.0
1 181 23.7
2 184 24.1
3 138 18.1
4 114 14.9
5 or more 109 14.3
aAmong Women Diagnosed With Breast Cancer During 1997–1998 Who
Completed the Follow-Up Interview in 2002–2003, Long Island, New York
bDomains include vitamin/mineral supplements, botanical supplements, other
natural products, mind-body techniques, special treatments, dietary change,
and practitioner-based complementary and alternative medicine treatments
Table 2 Use prevalence of commonly-used individual CAM modalities and CAM groupings, Long Island, New York (n = 764)a
No use Low dose High dose Median (IQR) cumulative doseb
Vitamin/mineral supplementsc 11 % 45 % 45 % 7.7 (2.0–19.0)
Echinacea 86 % 8 % 6 % 0.4 (0.1–0.6)
Green tea 77 % 15 % 8 % 0.6 (0.1–1.3)
Other herbsd 79 % 11 % 10 % 1.0 (0.4–4.5)
Natural productse 78 % 11 % 11 % 1.0 (0.4–4.6)
Mind-body techniquesf 59 % 20 % 20 % 19.3 (4.5–135.0)
Diet changeg 67 % 18 % 15 % 7.0 (4.5–12.0)
Massage 83 % 13 % 4 % 4.5 (2.0–4.5)
Chiropractic 82 % 9 % 9 % 3.3 (1.0–9.0)
Other practitioner-based CAMh 88 % 7 % 5 % 2.0 (1.0–3.5)
Abbreviations: CAM complementary and alternative medicine, IQR interquartile range
aIndicator variables were determined through factor analysis; CAM groupings represent clusters of individual modalities that tended to be practiced together;
cumulative dose for groupings was computed by summing cumulative doses of contributing modalities
bCumulative dose since diagnosis for vitamin/mineral supplements, echinacea, green tea, other herbs, and natural products, expressed as number of times taken
per day multiplied by years taken; for mind-body techniques, massage, chiropractic, and practitioner-based CAM, as number of times used per month times num-
ber of years taken; and for diet, as the number of combined years since diagnosis
cVitamin/mineral supplements includes all nutritional supplements that include multiple and single vitamins/minerals
dOther herbs includes all herbs and botanicals in pill, tea, extract, infusion, oil, powder, or cream form, with exception of echinacea and green tea
eNatural product includes all non-herbal, non-vitamin over-the-counter CAM products, predominantly glucosamine, fish oil, coenzyme Q10, flax seed oil,
and acidophilus
fMind-body techniques includes support groups; psychotherapy with social worker, psychologist, or psychiatrist; meditation; vizualization/imagery; hypnosis; Reiki,
healing touch or other energy therapy; tai chi; qi gong; yoga; dance therapy; art therapy; music therapy; and poetry therapy or journaling
gDiet changes considered were vegan/vegetarian; no red meat but do eat chcken and/or fish; organic fruits and vegetables; macrobiotic diet; low-fat diet; high
fiber diet; change consumption of soy products; diet or program designed to lose weight
hOther practitioner-based CAM includes acupuncture, ayurvedic medicine, traditional Chinese medicine, herbalist, homeopathy, Native American medicine, naturo-
pathic physician, nutritionist/dietician, tibetan medicine, or other practitioner based CAM treatments
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modality high-dose users” (9.1 %) was characterized by a
relatively high probability of using nearly all CAM mo-
dalities. Probabilities of CAM use conditional on latent
class membership are shown graphically in Fig. 1.
Predictors of latent class membership
Participants were classified into latent classes corre-
sponding to their highest posterior probability, as de-
rived from the LCA. The mean maximum posterior
probability was 0.83, ranging from 0.82 to 0.85 across
classes, suggesting low classification error (data not
shown). Predictors of membership in the vitamin/min-
eral supplement users, mind-body medicine users and
multi-modality high-doseusers classes were similar,
when compared with those of the low-dose supplement
users (Table 5 and Table 6). Predictors of membership in
classes characterized by substantial CAM use included
younger age, more education, higher income, Jewish reli-
gion, ideal body mass index, higher intake of fruits and
vegetables, higher levels of physical activity, receipt of
adjuvant chemotherapy, and prior use of oral
contraceptives.
Discussion
We identified four distinct classes of CAM users
through a latent class analysis of breast cancer survivors
with near-universal use of complementary and alterna-
tive medicine. Because much of that use involved vita-
min/mineral supplements, we termed as low-dose
supplement users patients who were likely to report
using common vitamin/mineral supplements but not
other CAM since diagnosis. Latent classes were charac-
terized by varying probabilities of using CAM products
and techniques in particular groupings.
Results of previous studies suggest that breast cancer
patients have a higher probability and more varied CAM
use than the general population. While estimates from
the 2002 National Health Interview Survey suggest that
those in the general population rarely use more than
one form of CAM [15], CAM use among breast cancer
patients usually involves multiple modalities [4, 6, 7].
Our results are consistent with this observation. Previ-
ous studies of breast cancer patients have shown that
younger age, higher education and income levels, and re-
ceipt of chemotherapy are associated with CAM use in
breast cancer patients and survivors [4, 6, 11, 12, 29].
Multi-modality high-dose users and mind-body medi-
cine users are those with a high probability of using mo-
dalities generally included in more conservative
definitions of CAM use, namely mind-body medicine
practices, practitioner-based treatments, and plant-based
remedies [29]. Compared with membership in the low-
dose supplement users class, membership in the other
Table 3 Model fit statistics for estimating classes of CAM users
through latent class analysis
Number
of classes
Likelihood
ratio G2
AIC BIC Sample size
Adjusted BIC
% of seeds
associated
with best fit
1 2903.8 2943.8 3036.5 2973.0 100 %
2 2313.5 2395.5 2585.7 2455.5 100 %
3 2202.8 2326.8 2614.4 2417.5 40 %
4a 2117.9 2283.9 2668.9 2405.3 100 %
5 2070.4 2278.4 2760.8 2430.6 36 %
6 2028.9 2278.9 2858.7 2461.8 13 %
7 1992.5 2284.5 2961.7 2498.1 3 %
Abbreviations: AIC Akaike Information Criterion, BIC Bayesian Information
Criterion, CAM complementary and alternative medicine
aSelected model contained 4 latent classes
Table 4 Use of CAM modalities since breast cancer diagnosis, conditional on latent class membershipa
Low-dose supplement
users (39.6 %)
Vitamin/mineral supplement
users (39.3 %)
Mind-body medicine users
(11.9 %)
Multi-modality high-dose
users (9.1 %)
Low dose High dose Low dose High dose Low dose High dose Low dose High dose
Vitamin/mineral supplements 0.59 0.19 0.34 0.63 0.52 0.41 0.19 0.81
Echinacea 0.00 0.00 0.11 0.07 0.17 0.05 0.19 0.30
Green tea 0.02 0.00 0.22 0.13 0.22 0.01 0.30 0.33
Other herbs 0.02 0.00 0.15 0.11 0.24 0.04 0.16 0.55
Natural products 0.03 0.01 0.15 0.13 0.28 0.00 0.11 0.58
Mind-body techniques 0.07 0.08 0.18 0.19 0.66 0.33 0.29 0.62
Diet change 0.16 0.02 0.22 0.17 0.15 0.19 0.12 0.54
Massage 0.02 0.00 0.03 0.02 0.60 0.13 0.37 0.18
Chiropractic 0.04 0.04 0.12 0.08 0.14 0.11 0.13 0.33
Other practitioner-based CAM 0.01 0.00 0.08 0.04 0.08 0.10 0.28 0.26
aProbabilities of class membership identified through latent class analysis. Number of classes determined based on model stability, fit statistics, and interpretability
of latent classes
Abbreviation: CAM, complementary and alternative medicine
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classes was strongly predicted by known correlates of
CAM use, lending credibility to our analytic approach.
To our knowledge only one prior study has assessed
CAM use patterns in cancer patients or survivors at the
individual level. A cluster analysis conducted by Hok
and colleagues in 38 cancer patients characterized CAM
users by their therapeutic preferences [7]. Four types of
CAM users emerged from their analysis, characterized
by the number of NCCAM domains used and a prefer-
ence for either energy therapies or alternative medical
systems and treatment centers. This differs from the
present study conducted among a population-based
sample of 764 breast cancer survivors in which the most
important modalities for discriminating classes were
mind-body techniques and massage. This discrepancy
is likely explained by differences in the selection of
participants, with the small previous study focused on
patients with a high commitment to CAM use, with
pervasive use of biological-based and mind-body CAM
modalities.
Ours is the first study of CAM in breast cancer pa-
tients to take into account a measure of relative
Fig. 1 Probability of reporting use of each CAM modality conditional on latent class membership. CAM use assessed in 2002–2003, since a first
primary breast cancer diagnosis in 1996–1997, among cases in the Long Island Breast Cancer Study Project, Long Island, New York. Probabilities
of class membership identified through latent class analysis; number of classes determined based on model stability, fit statistics, and
interpretability of latent classes; high cumulative dose refers to using each modality in excess of the median cumulative dose; abbreviation: CAM,
complementary and alternative medicine
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Table 5 Demographics and breast cancer risk factors by latent class of CAM use (n = 764)a,b
Total
sample
Low-dose
supplement users
Vitamin/mineral
supplement users
Mind-body
medicine users
Multi-modality high-
dose users
n %e n %e n %e n %e n %e
Demographics
Age in years, mean (SD)d 56.3 (11.4) 58.8 (12.0) 55.6 (10.5) 50.9 (9.8) 53.1 (10.0)
Age at diagnosisd
< 45 years 136 17.8 48 14.3 51 18.3 24 28.6 13 19.7
45–54 years 231 30.2 84 25.1 88 31.5 34 40.5 25 37.9
55–64 years 204 26.7 85 25.4 81 29.0 18 21.4 20 30.3
65+ years 193 25.3 118 35.2 59 21.2 8 9.5 8 12.1
Religionc
Protestant 173 22.6 82 24.5 65 23.3 13 15.5 13 19.7
Catholic 424 55.5 198 59.1 151 54.1 43 51.2 32 48.5
Jewish 153 20.0 49 14.6 58 20.8 27 32.1 19 28.8
Other/refused 14 1.8 6 1.8 5 1.8 f f f f
Annual household incomed
Less than $25,000 79 10.3 50 14.9 18 6.5 f f 7 10.6
$25,000–$49,999 234 30.6 127 37.9 81 29.0 13 15.5 13 19.7
$50,000–$89,999 266 34.8 100 29.9 94 33.7 44 52.4 28 42.4
Greater than $90,000 185 24.2 58 17.3 86 30.8 23 27.4 18 27.3
Educationd
High school graduate or less 301 39.4 185 55.2 92 33.0 10 11.9 14 21.2
Some college 195 25.5 77 23.0 72 25.8 28 33.3 18 27.3
College graduate 111 14.5 31 9.3 56 20.1 16 19.1 8 12.1
Postgraduate 157 20.6 42 12.5 59 21.2 30 35.7 26 39.4
Breast cancer risk factors
First degree family history of BC
No 595 77.9 256 76.4 217 77.8 65 77.4 57 86.4
Yes 151 19.8 66 19.7 59 21.2 19 22.6 7 10.6
Prior oral contraceptive used
Never 376 49.2 190 56.7 135 48.4 25 29.8 26 39.4
Ever 386 50.5 144 43.0 143 51.3 59 70.2 40 60.6
Prior hormone replacement therapy use
Never 511 66.9 236 70.5 187 67.0 52 61.9 36 54.6
Ever 253 33.1 99 29.6 92 33.0 32 38.1 30 45.5
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Table 5 Demographics and breast cancer risk factors by latent class of CAM use (n = 764)a,b (Continued)
Menopausal status at diagnosisd
Pre-menopausal 279 36.5 87 26.0 117 41.9 45 53.6 30 45.5
Post-menopausal 465 60.9 239 71.3 158 56.6 38 45.2 30 45.5
BMI at diagnosisd
< 25 375 49.1 139 41.5 158 56.6 36 42.9 42 63.6
25–29 241 31.5 113 33.7 86 30.8 27 32.1 15 22.7
30+ 143 18.7 80 23.9 34 12.2 20 23.8 9 13.6
Abbreviations: BC breast cancer, BMI body mass index, CAM complementary and alternative medicine, SD standard deviation
aParticipants assigned to class based on highest posterior class membership probability, as determined through SAS PROC LCA
bP-values based on Pearson chi-squared tests or analysis of variance (ANOVA)
cP < 0.05
dP < 0.001
eColumn percentages may not add up to 100 due to missing data
fValues not displayed due to cell sizes < 5
Table 6 Health behaviors and clinical characteristics by latent class of CAM use (n = 764)a,b
Total
sample
Low-dose
supplement users
Vitamin/mineral
supplement users
Mind-body
medicine users
Multi-modality
high-dose users
n %e n %e n %e n %e n %e
Health behaviors
Mammogram
No mammogram in last 5 years 32 4.2 19 5.7 8 2.9 f f f f
Had mammogram <5 years ago 721 94.4 309 92.2 268 96.1 80 95.2 64 97.0
Cigarette smoking statusc
Never 337 44.1 137 40.9 130 46.6 46 54.8 24 36.4
Current 142 18.6 70 20.9 56 20.1 6 7.1 10 15.2
Former 285 37.3 128 38.2 93 33.3 32 38.1 32 48.5
Alcohol use
Never 258 33.8 120 35.8 86 30.8 32 38.1 20 30.3
Ever 506 66.2 215 64.2 193 69.2 52 61.9 46 69.7
Physical activity since menarched
None 185 24.2 110 32.8 51 18.3 18 21.4 6 9.1
0–0.69 h/week 172 22.5 77 23.0 57 20.4 23 27.4 15 22.7
0.70–2.6 h/week 184 24.1 81 24.2 70 25.1 13 15.5 20 30.3
≥ 2.7 h/week 181 23.7 52 15.5 81 29.0 28 33.3 20 30.3
Fruit and vegetable intaked
0–34 servings per week 475 62.2 238 71.0 159 57.0 42 50.0 36 54.6
≥ 35 servings per week 281 36.8 95 28.4 116 41.6 40 47.6 30 45.5
Clinical characteristics
Stage at diagnosis for first primary
In situ 137 17.9 52 15.5 48 17.2 23 27.4 14 21.2
Invasive 627 82.1 283 84.5 231 82.8 61 72.6 52 78.8
Hormone receptor status for first primary BC
ER- / PR- 99 13.0 43 12.8 37 13.3 35 41.7 5 7.6
ER- / PR+ 27 3.5 11 3.3 14 5.0 14 16.7 f f
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cumulative CAM dose. Here, a salient aspect of vitamin/
mineral supplement users was their tendency to use sup-
plements at a higher intensity/duration than low-dose
supplement users. We believe differentiating users
based on this factor enhances identification of sub-
groups of breast cancer patients who are often users of
multiple CAM modalities, even though incorporating
this strategy weakens precision of parameter estimates.
Indeed, data sparseness that resulted from pairing this
added complexity of the large number of LCA indi-
cator variables with our relatively small sample size
necessitated collapsing CAM modalities prior to per-
forming the LCA [30]. Limited sample sizes in future
studies may necessitate aggregating CAM practices
using factor analysis as done here, or by combining
similar treatment modalities, prior to performing the
LCA. Additional strengths of this study include the
rigorous consideration of covariates and comprehen-
sive CAM assessment.
Because data on frequency of CAM use were available
only during active breast cancer treatment, the cumula-
tive dose component of the analysis was calculated by
extrapolating the frequency of use during treatment to
all time since diagnosis. Bias therefore may have been in-
troduced regarding modalities correlated with conven-
tional treatments. The findings may also reflect selection
bias because non-responders differed from participants
on several predictors of CAM use [10]. Other limitations
include lack of adjustment for multiple comparisons, al-
though consistency with prior studies lends credibility to
the results. It is not clear how these findings may be
generalized to different regions and more diverse popu-
lations, and whether the use patterns identified here are
still relevant to more recently diagnosed breast cancer
patients on Long Island.
Conclusion
In conclusion, this analysis of breast cancer patients sug-
gests four subgroups of women characterized by their
use of multiple complementary therapies simultaneously.
A large proportion (71.3 %) of study participants re-
ported using two or more forms of CAM following diag-
nosis and nearly 10 % were committed users of multiple
modalities. Latent class analysis was shown to be an ef-
fective method for grouping individual breast cancer pa-
tients based on multidimensional patterns of CAM use.
The generalizability of the latent classes identified here
to populations with different socio-demographic and
clinical characteristics remains to be determined. How-
ever, LCA presents a nuanced approach to data reduc-
tion and subgroup analysis in populations with high use
of multiple forms of CAM. Further research using LCA-
derived classes may be especially useful to investigate
causal relationships between CAM and cancer out-
comes among patients who use more than one CAM
modality.
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